Rhodiola Rosea
AdaptogenAlso known as: Rhodiola · Arctic root · Golden root · Rosavin
An adaptogenic herb studied for stress resistance, mental fatigue, and exercise performance. Standardized extracts contain rosavins and salidroside. Shorter studied duration than ashwagandha.
How expert claims hold up
9 of 18 claims assessed2 of 9 assessed claims supported or partially supported by published research
Evidence Summary
Rhodiola rosea has accumulated a broader base of human research than most other adaptogens, spanning randomized controlled trials (RCTs), systematic reviews, and meta-analyses across domains including mental stress, physical performance, mood, and cognitive function. However, the available study data provided here largely lacks reported key findings, sample sizes, and population details, which substantially limits the strength of any conclusions that can be drawn. What the evidence base does suggest is that Rhodiola is at minimum a legitimate subject of scientific inquiry — not merely a marketing construct — with study designs rigorous enough (including triple-blinded, placebo-controlled, crossover trials) to take seriously, even if definitive efficacy conclusions remain elusive. The research covers a diverse set of outcomes: physical performance in athletes, cognitive performance in healthy adults, mood and milder depressive symptoms, stress axis (HPA axis) modulation, premenstrual syndrome management, digital eye strain, and sleep. Notably, a WFSBP/CANMAT clinical guideline review and multiple strong-quality systematic reviews and meta-analyses are present in the literature pool, suggesting that Rhodiola has reached a threshold of evidence warranting inclusion in formal clinical discussions. Salidroside, one of Rhodiola's key active compounds, has been studied independently in exercise contexts. Despite this breadth, the majority of individual expert claims about Rhodiola were rated as having insufficient evidence, with only two claims receiving even partial support — indicating that specific, confident assertions about its benefits outpace what the data can currently confirm. Several important caveats apply. Most of the RCTs identified appear to be moderate in quality rather than strong, and critical details — including sample sizes, specific populations studied, and quantified outcomes — were unavailable in the data provided, preventing precise effect-size interpretation. Many studies appear short-term, making it impossible to draw conclusions about sustained use. It is also unclear whether findings from one population (e.g., trained athletes or adults with mild depression) generalize to others. The combination supplement study (Rhodiola plus caffeine) further complicates attribution of any effects to Rhodiola alone. Until more fully reported, large-sample RCTs are available with consistent outcome measures, claims about Rhodiola's specific benefits should be held with measured skepticism.
Read full evidence summary →Top studies
Clinician guidelines for the treatment of psychiatric disorders with nutraceuticals and phytoceuticals: The World Federation of Societies of Biological Psychiatry (WFSBP) and Canadian Network for Mood and Anxiety Treatments (CANMAT) Taskforce.
Clinician guidelines for the treatment of psychiatric disorders with nutraceuticals and phytoceuticals: The World Federation of Societies of Biological Psychiatry (WFSBP) and Canadian Network for Mood and Anxiety Treatments (CANMAT) Taskforce.
Efficacy of Pharmacological Interventions in Milder Depression: A Systematic Review and Meta-Analysis.
Efficacy of Pharmacological Interventions in Milder Depression: A Systematic Review and Meta-Analysis.
Expert Mentions
All 18 mentions"I want to be careful here because depression is a serious medical condition, and I'm not recommending Rhodiola as a primary treatment. But it's intriguing that an adaptogen might have genuine effects on mood and stress hormones."
Huberman notes it is intriguing that an adaptogen might have genuine effects on mood and stress hormones, while cautioning he is not recommending Rhodiola as a primary treatment for depression.
"I want to be careful here because depression is a serious medical condition, and I'm not recommending Rhodiola as a primary treatment. But it's intriguing that an adaptogen might have genuine effects on mood and stress hormones."
Huberman notes it is intriguing that an adaptogen might have genuine effects on mood and stress hormones, while cautioning he is not recommending Rhodiola as a primary treatment for depression.
None of the 10 provided studies directly examine Rhodiola rosea's effects on mood or stress hormones (e.g., cortisol) in the context of depression treatment. The available studies focus primarily on exercise performance, digital eye strain, premenstrual syndrome, and sleep — not on mood regulation or neuroendocrine stress responses. The WFSBP/CANMAT meta-analysis (PMID 35311615) is potentially the most relevant study for evaluating adaptogen use in psychiatric contexts, but no key findings are reported, making it impossible to draw conclusions. Because Huberman's claim is itself a cautious, exploratory observation rather than a strong therapeutic assertion, the absence of directly applicable evidence means it can neither be confirmed nor refuted from this dataset.
Key findings
- ·Rhodiola rosea is among the better-studied adaptogens, with human trial designs ranging from double- and triple-blinded RCTs to meta-analyses and clinical guideline reviews — a level of scrutiny rare in the herbal supplement space.
- ·Research spans multiple outcome domains including physical performance, cognitive function, mood/mild depression, HPA axis stress response, and sleep, suggesting broad interest but also a lack of concentrated focus on any single indication.
- ·Formal clinical bodies (WFSBP and CANMAT) have included Rhodiola in nutraceutical treatment guidelines for psychiatric disorders, indicating it has crossed a threshold of evidence relevant to clinicians.
Evidence gaps
- ·Most available studies appear to be short-term, leaving long-term safety, efficacy, and optimal dosing duration largely unknown.
- ·Critical study details — including sample sizes, specific populations, and quantified effect sizes — were not available in the current data, making it impossible to assess the practical magnitude of any benefits.
- ·It remains unclear whether findings from specific subgroups (e.g., trained athletes, adults with mild depression) apply broadly to healthy general populations, limiting the generalizability of existing research.